The aim of the study will be to determine the diagnostic and prognostic value of elastosonography and the use of the contrast agent (Sonovue®) in the endoscopic ultrasound exploration of deep pelvic endometriosis.
No linked publications found in PubMed
Inclusion Criteria: * Woman over 18 years of age * Diagnosis of deep pelvic endometriosis (clinical and / or MRI and / or transvaginal ultrasound), defined by penetrating endometriosis lesions in the retroperitoneal space and / or pelvic organ wall at a depth of at least 5 millimeters , with digestive impairment. * Presenting symptoms of deep pelvic endometriosis disabling and / or fertility difficulties and requiring an exhaustive iconographic assessment. * Belong to a social security scheme. * Signature of informed consent. Exclusion Criteria: * Without medical contraindication to the realization of a low digestive endoscopy. * Allergy or hypersensitivity to sulfur hexafluoride or one of the components of Sonovue® (contrast agent used in endoscopy ultrasound). * Severe heart rhythm disorders. * Angina unstable. * Recent Acute Coronary Syndrome. * Heart Shunt Right - Left. * Severe pulmonary arterial hypertension (PAH) (defined as PAH \> 90 mmHg). * Acute or severe cardiac insufficiency stage 3 and 4 * Pregnant woman and vulnerable patient population (persons deprived of administrative and / or judicial liberty, and persons under guardianship. * Mental disability of the subject making participation in the trial impossible.